Plasminogen receptors and their role in the pathogenesis of inflammatory, autoimmune and malignant disease

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 1, 2013, Pages 26-34

  Godier, A ^a,b   Hunt, B J ^c,d  

^a Institut Cochin   (France)

^b INSERM   (France)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Fibrinolysis; Inflammation; Plasminogen; Receptors; Thrombosis; Tumorogenesis

Indexed keywords

BETA2 GLYCOPROTEIN 1; ENOLASE; ENOLASE 1; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE H2B; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE 1; LIPOCORTIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMIN; PLASMINOGEN; PROTEIN S 100; S100A10 PROTEIN; SCLEROPROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL INVASION; CELL MIGRATION; CELL SURFACE; CRYSTAL STRUCTURE; DNA REPAIR; DNA REPLICATION; HUMAN; INFLAMMATORY DISEASE; METASTASIS; NEOPLASM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; ANNEXIN A2; AUTOIMMUNE DISEASES; HISTONES; HUMANS; INFLAMMATION; MULTIPROTEIN COMPLEXES; NEOPLASMS; PHOSPHOPYRUVATE HYDRATASE; PLASMINOGEN; RECEPTORS, CELL SURFACE; S100 PROTEINS; SIGNAL TRANSDUCTION;

EID: 84873047947     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12064     Document Type: Review

References (58)

1. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
2. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012; 344: e3054.
3. Verheugt FW. Acute myocardial infarction associated with ST segment elevation and the new European Society of Cardiology guidelines. Heart 2009; 95: 1112-7.
4. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009: CD000213.
5. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-21.
6. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003; 89: 409-19.
7. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
8. Petersen TE, Martzen MR, Ichinose A, Davie EW. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990; 265: 6104-11.
9. Christen MT, Frank P, Schaller J, Llinas M. Human plasminogen kringle 3: solution structure, functional insights, phylogenetic landscape. Biochemistry 2010; 49: 7131-50.
10. Marti DN, Hu CK, An SS, von Haller P, Schaller J, Llinas M. Ligand preferences of kringle 2 and homologous domains of human plasminogen: canvassing weak, intermediate, and high-affinity binding sites by 1H-NMR. Biochemistry 1997; 36: 11591-604.
11. Xue Y, Bodin C, Olsson K. Crystal structure of the native plasminogen reveals an activation-resistant compact conformation. J Thromb Haemost 2012; 10: 1385-96.
12. Law RH, Caradoc-Davies T, Cowieson N, Horvath AJ, Quek AJ, Encarnacao JA, Steer D, Cowan A, Zhang Q, Lu BG, Pike RN, Smith AI, Coughlin PB, Whisstock JC. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012; 1: 185-90.
13. Gong Y, Kim SO, Felez J, Grella DK, Castellino FJ, Miles LA. Conversion of Glu-plasminogen to Lys-plasminogen is necessary for optimal stimulation of plasminogen activation on the endothelial cell surface. J Biol Chem 2001; 276: 19078-83.
14. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J 1995; 9: 939-45.
15. Hawley SB, Tamura T, Miles LA. Purification, cloning, and characterization of a profibrinolytic plasminogen-binding protein, TIP49a. J Biol Chem 2001; 276: 179-86.
16. Parkkinen J, Rauvala H. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J Biol Chem 1991; 266: 16730-5.
17. Gonias SL, Hembrough TA, Sankovic M. Cytokeratin 8 functions as a major plasminogen receptor in select epithelial and carcinoma cells. Front Biosci 2001; 6: D1403-11.
18. Miles LA, Ginsberg MH, White JG, Plow EF. Plasminogen interacts with human platelets through two distinct mechanisms. J Clin Invest 1986; 77: 2001-9.
19. Dudani AK, Ganz PR. Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Br J Haematol 1996; 95: 168-78.
20. Felez J, Chanquia CJ, Fabregas P, Plow EF, Miles LA. Competition between plasminogen and tissue plasminogen activator for cellular binding sites. Blood 1993; 82: 2433-41.
21. Takada Y, Makino Y, Takada A. Glu-plasminogen I and II: their activation by urokinase and streptokinase in the presence of fibrin and fibrinogen. Thromb Res 1985; 39: 289-96.
22. Gonzalez-Gronow M, Gawdi G, Pizzo SV. Tissue factor is the receptor for plasminogen type 1 on 1-LN human prostate cancer cells. Blood 2002; 99: 4562-7.
23. Madureira PA, Surette AP, Phipps KD, Taboski MA, Miller VA, Waisman DM. The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood 2011; 118: 4789-97.
24. Deora AB, Kreitzer G, Jacovina AT, Hajjar KA. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem 2004; 279: 43411-8.
25. Das R, Burke T, van Wagoner DR, Plow EF. L-type calcium channel blockers exert an antiinflammatory effect by suppressing expression of plasminogen receptors on macrophages. Circ Res 2009; 105: 167-75.
26. MacLeod TJ, Kwon M, Filipenko NR, Waisman DM. Phospholipid-associated annexin A2-S100A10 heterotetramer and its subunits: characterization of the interaction with tissue plasminogen activator, plasminogen, and plasmin. J Biol Chem 2003; 278: 25577-84.
27. Swisher JF, Khatri U, Feldman GM. Annexin A2 is a soluble mediator of macrophage activation. J Leukoc Biol 2007; 82: 1174-84.
28. Li Q, Ke F, Zhang W, Laumonnier Y, Syrovets T, Simmet T, Wang H. A role for the annexin A2 amino-terminal peptide in the plasmin-induced activation of human peripheral monocytes. Mol Immunol 2010; 47: 2405-10.
29. Swisher JF, Burton N, Bacot SM, Vogel SN, Feldman GM. Annexin A2 tetramer activates human and murine macrophages through TLR4. Blood 2010; 115: 549-58.
30. O'Connell PA, Surette AP, Liwski RS, Svenningsson P, Waisman DM. S100A10 regulates plasminogen-dependent macrophage invasion. Blood 2010; 116: 1136-46.
31. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004; 113: 38-48.
32. Surette AP, Madureira PA, Phipps KD, Miller VA, Svenningsson P, Waisman DM. Regulation of fibrinolysis by S100A10 in vivo. Blood 2011; 118: 3172-81.
33. Cesarman-Maus G, Rios-Luna NP, Deora AB, Huang B, Villa R, Cravioto Mdel C, Alarcon-Segovia D, Sanchez-Guerrero J, Hajjar KA. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006; 107: 4375-82.
34. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2012; 119: 884-93.
35. Cesarman-Maus G, Cantu-Brito C, Barinagarrementeria F, Villa R, Reyes E, Sanchez-Guerrero J, Hajjar KA, Latorre EG. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke 2011; 42: 501-3.
36. Sharma M, Ownbey RT, Sharma MC. Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 2010; 88: 278-86.
37. Choi KS, Fogg DK, Yoon CS, Waisman DM. p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB J 2003; 17: 235-46.
38. Wang CY, Chen CL, Tseng YL, Fang YT, Lin YS, Su WC, Chen CC, Chang KC, Wang YC, Lin CF. Annexin A2 silencing induces G2 arrest of non-small cell lung cancer cells through p53-dependent and -independent mechanisms. J Biol Chem 2012; 287: 32512-24.
39. Sharma M, Blackman MR, Sharma MC. Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol 2011; 92: 175-84.
40. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 994-1004.
41. Liu Y, Wang Z, Jiang M, Dai L, Zhang W, Wu D, Ruan C. The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leuk Res 2011; 35: 879-84.
42. Kwaan HC, Wang J, Weiss I. Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin. J Thromb Haemost 2004; 2: 306-12.
43. Breen KA, Grimwade D, Hunt BJ. The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 2012; 156: 24-36.
44. Falanga A, Consonni R, Marchetti M, Mielicki WP, Rambaldi A, Lanotte M, Gordon SG, Barbui T. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. Leukemia 1994; 8: 156-9.
45. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 2001; 58: 902-20.
46. Kang HJ, Jung SK, Kim SJ, Chung SJ. Structure of human alpha-enolase (hENO1), a multifunctional glycolytic enzyme. Acta Crystallogr D Biol Crystallogr 2008; 64: 651-7.
47. Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J, Markart P, Preissner KT. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 2009; 113: 5588-98.
48. Capello M, Ferri-Borgogno S, Cappello P, Novelli F. Alpha-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J 2011; 278: 1064-74.
49. Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, Migliorini P, Salacone P, Novarino A, Giacobino A, Ciuffreda L, Alessio M, Nistico P, Scarpa A, Pederzoli P, Zhou W, Petricoin EF III, Liotta LA, Giovarelli M, Milella M, Novelli F. Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer. J Proteome Res 2011; 10: 105-12.
50. Herren T, Burke TA, Das R, Plow EF. Identification of histone H2B as a regulated plasminogen receptor. Biochemistry 2006; 45: 9463-74.
51. Das R, Burke T, Plow EF. Histone H2B as a functionally important plasminogen receptor on macrophages. Blood 2007; 110: 3763-72.
52. Das R, Plow EF. Phosphatidylserine as an anchor for plasminogen and its plasminogen receptor, histone H2B, to the macrophage surface. J Thromb Haemost 2011; 9: 339-49.
53. Monestier M, Decker P, Briand JP, Gabriel JL, Muller S. Molecular and structural properties of three autoimmune IgG monoclonal antibodies to histone H2B. J Biol Chem 2000; 275: 13558-63.
54. Hasegawa M, Sato S, Kikuchi K, Takehara K. Antigen specificity of antihistone antibodies in systemic sclerosis. Ann Rheum Dis 1998; 57: 470-5.
55. Sato S, Kodera M, Hasegawa M, Fujimoto M, Takehara K. Antinucleosome antibody is a major autoantibody in localized scleroderma. Br J Dermatol 2004; 151: 1182-8.
56. Williams WM, Whalley AS, Comacchio RM, Rosenberg J, Watts RA, Isenberg DA, McCutchan JA, Morrow WJ. Correlation between expression of antibodies to histone H2B and clinical activity in HIV-infected individuals. Clin Exp Immunol 1996; 104: 18-24.
57. Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, Kamps MP, Yates JR III, Parmer RJ, Miles LA. Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood 2010; 115: 1319-30.
58. Lighvani S, Baik N, Diggs JE, Khaldoyanidi S, Parmer RJ, Miles LA. Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT. Blood 2011; 118: 5622-30.